LAUSR

Mobocertinib: First Approval

Sign Up to like & get
recommendations!
0 Published in 2021 at "Drugs"

DOI: 10.1007/s40265-021-01632-9

Abstract: Mobocertinib (EXKIVITY™) is a first-in-class EGFR tyrosine kinase inhibitor being developed for the treatment of EGFR exon 20 insertion (EGFRex20ins) -positive non-small cell lung cancer (NSCLC). Based on efficacy in patients whose disease had progressed… read more here.

Keywords: first approval; mobocertinib; mobocertinib first; approval ... See more keywords